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Introduction
Multiple sclerosis (MS), a chronic demyelinating disease, more common in women than in men, is frequently diagnosed in young patients during their peak reproductive years. 1 Although MS has not been shown to increase the rate of adverse pregnancy outcomes, 2 information regarding the risk associated with exposure to disease-modifying therapies (DMTs) has been limited. Animal data suggested an increased risk of early pregnancy losses. Studies in humans had sample sizes too small to draw firm conclusions; therefore, we aim to use a pharmacovigilance (PV) database as an alternative source of information on exposure during pregnancy, which is crucial for guiding decision-making during this time period. Current data on DMT exposure during pregnancy are limited by small sample sizes and the potential for reporting bias. As such, guidelines for the treatment offer little guidance on DMTs during pregnancy, suggesting that patients consider deferring DMTs until after pregnancy. 3, 4 Discontinuation of DMTs for several months by patients who intend to become pregnant might also precipitate the reactivation of well-controlled MS, which could result in accumulated neurological disability. Concerns also arise when patients have an unplanned pregnancy during treatment. 5 Interferon beta-1b (Betaferon ® /Betaseron ® , Bayer AG;
Extavia, Novartis Pharmaceuticals Corporation) demonstrated a favorable safety and efficacy profile in patients with clinically isolated syndrome suggestive of MS, relapsing MS, and secondary progressive MS. [6] [7] [8] [9] [10] [11] [12] [13] Some preliminary evidence on the effects of exposure during pregnancy has been reported, suggesting a relatively low risk of abnormal outcomes. 14, 15 In the present study, we aimed to strengthen the data regarding interferon beta-1b exposure during pregnancy by analyzing a large sample size from a PV database.
Methods
Pregnancy cases with exposure to interferon beta-1b reported to Bayer from worldwide sources up to February 2018 were retrieved from Bayer's global PV database for this retrospective cohort study. All cases were assessed for medical confirmation (confirmed versus unconfirmed), as the medically confirmed cases would present to be more reliable sources of information than patientreported cases. However, all cases received the same level of surveillance with similar follow-up processes. The database contains data on more than 3800 pregnancies with exposure to interferon beta-1b collected over more than 20 years since January 1995, making it the largest dataset available on interferon beta-1b exposure to date, and the source of many cases that can be assessed for patterns of outcomes.
In order to limit the potential for recall bias in the dataset, only prospective cases (patients who have been exposed to interferon beta-1b but whose data were entered into the database prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation) 16, 17 were included in the present analysis as retrospective pregnancy cases (data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation) have an inherent reporting bias toward adverse outcomes as normal outcomes are less likely to be reported. 16, 17 This may lead to a higher proportion of abnormal outcomes that does not reflect the 'true' prevalence rate. 16 All considered cases were consistent with the European Medicines Agency guidelines on exposure to medicinal products during pregnancy. 16 The database included pregnancies that were reported spontaneously, during clinical trials, in registries, or through patient support programs, where patients were supervised by nursing staff when the pregnancies were confirmed. Outcomes and follow-up information were collected from patients and their health care providers. Institutional Review Board (IRB) approval was not required for the analysis of these PV data.
The calculations of rates for pregnancy losses were based on the total number of known pregnancies outcomes and the rates of outcomes after birth were based among the total number of cases with known live birth outcomes. Calculations of outcomes were conducted using the following formulas:
(1) Rate of live births = (total live births/total number known pregnancy outcomes) × 100 (2) Rate of spontaneous abortions = (total number of spontaneous abortions/total number of known pregnancy outcomes) × 100 (3) Rate of congenital anomalies = (total pregnancies with congenital anomaly/total number of live births with known outcomes) × 100
For these calculations, live births included those classified as a healthy child, nonhealthy child, congenital anomaly, and live birth with missing information on health status. The congenital anomalies were registered in the safety database and described 'as reported,' and were classified as per ICD-10 exclusively for this study by the authors with the intention to facilitate and group the terms. Pregnancy losses included ectopic pregnancies, spontaneous abortions, stillbirth/ fetal death. We defined spontaneous abortions as pregnancy losses occurring at less than 22 weeks gestation without elective medical or surgical intervention, which includes the subdivision of threatened abortions, incomplete abortions, inevitable abortions, missed abortions, septic abortions, complete abortions, and recurrent spontaneous abortions. 16, 18 After 22 weeks, live births, or stillbirths, were defined as the complete expulsion or extraction of products of conception at any point during gestation. 16 Spontaneous abortions were compared with reference rates of abnormal pregnancy outcomes journals.sagepub.com/home/tan 3 from the general population. Rates of pregnancies resulting in congenital disorders in the database were compared with rates from the general population using the EUROCAT database, a European network of population-based registries for the epidemiologic surveillance of congenital anomalies (2012-2016), 19 and the Metropolitan Atlanta Congenital Defects Program (MACDP) database, a US population-based system that records birth defects . 20 Approximately 80% of the case reports came from the United States and Europe, and, therefore, these American and European databases were considered appropriate for comparison. The exact Clopper Pearson method was used to calculate 95% confidence intervals (95% CIs). The standardized incidence ratio (SIR) for birth defects was calculated as the ratio of observed to expected events, with 95% CI calculated using the exact Poisson method by Owen. Any SIR smaller than 1.00 indicated a lower than expected number of birth defects.
Results
As of February 2018, there were a total of 3884 pregnancy cases in the database, of which 2581 prospective pregnancies exposed to interferon beta-1b were retrieved from 2548 individual case safety reports ( Figure 1 ). A total of 1348 pregnancies had documented outcomes and were included in the data analyses regardless of gestational age. The majority of cases came from North America (43%, including 37% from the US) and Europe (41%, including 22% from Germany) ( Figure 2 ). Most of the cases (83%) were solicited from observational studies and Patient Support Programs. From the remaining spontaneous reports (17%), 62% were medically confirmed. Most exposures (59.6%) occurred during the first trimester ( Table 1 ). Therapeutic abortion A separate analysis was conducted to assess the potential for bias in retrospectively reported cases within the database. A total of 1303 cases were retrospectively reported to the database (i.e. after pregnancy outcome was already known). Within the retrospective subset, 1219 cases (93.6%) included known pregnancy outcomes, compared with 47.8% of prospective cases. Timing of interferon beta-1b exposure was unknown in 58.8% of retrospective cases. The percentage of live births in the retrospective subset was 69.2% (compared with 82.0% in the prospective subset). Negative pregnancy outcomes were reported more frequently in the retrospective cohort than in the prospective cohort, including spontaneous abortions (21.2% versus 11.9%) and congenital anomalies (5.6% versus 1.4%).
Discussion
In this study containing the largest worldwide sample of patients exposed to interferon beta-1b during pregnancy reported in the global PV database, we did not find an increase in the rate of abnormal pregnancy outcomes. Rates of spontaneous abortion and major or minor birth defects were not higher than background estimates from the general population. Therefore, our data provide important information showing that firsttrimester exposure to interferon beta-1b did not increase the risk of adverse pregnancy outcomes.
It is important to note that the rates of birth defects in the present analysis were lower than those reported in population data, and the SIR suggested a lower than expected rate of birth defects. However, the 95% CIs for these calculations were relatively wide and the upper limits a Including live births that reported events which are not congenital anomalies (for example, neonatal jaundice). b Live births where there was no complete information on child health status so congenital anomalies could not be excluded. were close to the expected population range, suggesting that there is no meaningful difference between the present study and the MADCP or EUROCAT data. While these wide CIs were likely driven by the relatively small number of congenital anomalies, this study still captured the largest sample of interferon beta-1b-exposed patients to date, and, therefore, had the highest statistical power to measure these outcomes.
Only prospective cases were used to estimate prevalence rates of abnormal pregnancy outcomes. A strength of using prospective cases is that it allows for the calculation of an estimated risk, as the occurrence of adverse events and total number of exposure pregnancies are known. 17 Retrospective pregnancy cases have an inherent reporting bias because they may be influenced by the outcome itself, distorting the actual rates of these adverse outcomes, and may lead to unfounded fears among pregnant women who could benefit from the continuation of the treatment. 17, [21] [22] [23] Indeed this potential bias is shown in the higher rates of spontaneous abortion and congenital anomalies in retrospectively reported cases relative to the prospectively reported cases in the interferon beta-1b PV database. Consequently, this prospective sample, the largest sample of patients with exposure to interferon beta-1b during pregnancy reported to date, more accurately reflects the effects of interferon beta-1b on pregnancy outcomes.
Results similar to this study have been reported in other analyses of beta interferon exposure during pregnancy. The 99 interferon beta-1b-exposed pregnancies captured in the prospective US Betaseron Pregnancy Registry resulted in 83 (86.4%) live births, 11 (11.5%) spontaneous abortions, and 5 (5.8%) cases with birth defects. 14 An additional registry that collected data from patients in Italy exposed to interferon beta during pregnancy found that only 7 of 88 pregnancies (8%) resulted in spontaneous abortion, and no significant fetal complications were observed in live births. 24 Recent registries with interferon beta in pregnancy have shown rates for congenital anomalies that vary from 1.8% to 3.08%. 25, 26 A study using 445 pregnancies (251 exposed interferon beta, 194 unexposed to DMTs) data from the German Multiple Sclerosis Pregnancy Registry observed that the congenital anomaly rates in live births from interferon beta exposed patients versus patients without DMT exposure to be 3.08% (7/226) versus 5.52% (10/179) (p = 0.197), respectively. 25 In the past decade, the shift toward preventing disease activity as a goal of treatment has renewed the interest of patients in family planning because patients with MS may face a future with reduced disease-related neurological disability. In fact, pregnancy rates in women with MS have increased over the past several years, in contrast to the trend in the general population of North America of decreasing pregnancy rates. 27 Available data suggest that the rate of relapses may decrease during pregnancy; however, natural history studies showed that relapse rates increase after birth. 28 There is also evidence to suggest that the risk of postpartum relapses and disability is higher in women with more disease activity before and during pregnancy. 29, 30 The findings from these studies examining relapse and disability before, during, and after pregnancy underline the importance of controlling disease activity with DMTs until pregnancy starts. Therefore, it is crucial to assess which DMTs for MS can be considered as having a positive benefitrisk ratio when used during conception, pregnancy, and/or breastfeeding. 31, 32 The results of the present database analysis suggest that the rates of abnormal pregnancy outcomes in women exposed to interferon beta-1b until conception, and during the first trimester of pregnancy, did not exceed those of the general population. This information is important when a patient plans a pregnancy, taking into consideration the balance between the potential harms that may arise from discontinuation of treatment with interferon beta-1b against the benefit of continuing the treatment until pregnancy is confirmed.
The characteristics of the interferon beta-1b molecule may limit the possibility of harmful effects during pregnancy. For example, the relatively large size of the molecule may prevent it from crossing the placental barrier. 33, 34 In addition, the half-life may be relatively short, such that it limits the opportunities for interferon beta-1b molecules to come in contact with the developing fetus.
Limitations of the present study include generally known limitations inherent in data from PV databases, namely the lack of a direct comparator group, the potential for underreporting, 35 or for inaccurate or incomplete records, as records are based partly on voluntary reporting from health care professionals and patients. Consequently, the data depend on the individual quality of reports, which is a well-known limitation of spontaneous reporting. 17 The data included in our study are 'as reported,' and, therefore, rely on the reporters' accuracy. Furthermore, we cannot disregard the fact that some patients may have been exposed to numerous medications, and the possibility of incorrectly making the association of the pregnancy outcome with the other various treatments the patients were taking. Although spontaneous abortions are commonly said to occur in 15-20% of pregnancies, total spontaneous abortions could be much higher if losses that occur prior to clinical recognition are taken into consideration. 36 Patient records in this analysis also primarily reflect exposure to interferon beta-1b during the first trimester of pregnancy; data on exposure during the second and third trimesters were collected from a limited number of patients. However, the first 22 weeks are those most critical with the highest risk of congenital anomalies as well as the most likely clinical scenario for patients on interferon beta-1b. Comparisons to unexposed patients with MS, and/or non-MS controls, would have been helpful, and such comparisons are difficult when working with PV data. Consequently, analyses of PV with comparisons to population data have been implemented successfully in the past. 37, 38 Furthermore, the comparison with population data should take into consideration that PV data represents reporting rates while SIR uses incidence rates.
This PV data review is the largest interferon beta-1b dataset evaluated for pregnancy exposure. The data presented here provide evidence that interferon beta-1b exposure during pregnancy did not lead to a pattern of negative pregnancy outcomes.
The results of this analysis should add to the body of knowledge to help physicians and patients in their benefit-risk evaluation, and to make a more informed decision on treatment when planning pregnancy.
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